Latest by Judith A. Aberg, M.D., F.I.D.S.A.

Supreme Court Decision on Affordable Care Act Offers Great Promise in Fight Against AIDS

The Supreme Court ruling today upholding the Affordable Care Act (ACA) as the law of the land is a significant victory for people with HIV infection and the public health of our nation. The ACA corrects the injustices of our current health system, wh...

By Judith A. Aberg, M.D., F.I.D.S.A. for HIV Medicine Association

A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir

Controversy still exists regarding which is the best antiretroviral therapy (ART) to start with. We all agree that the regimen must be potent, safe, well tolerated, convenient for the individual, and must demonstrate both efficacy and durability.

An...

By Judith A. Aberg, M.D., F.I.D.S.A.

Using Genotypic Inhibitory Quotient to Measure Response to Boosted-Amprenavir Regimen

Efficacy of Ritonavir/Amprenavir-Containing Regimen in HIV-1 Protease Inhibitor-Experienced Patients and Predictivity of the Delta Viral Load Values Up to Week 24 Using Genotypic Inhibitory Quotient (Oral 165) Authored by A.G. Marcelin, C. Lamo...

By Judith A. Aberg, M.D., F.I.D.S.A.

Protease Inhibitors and Severe Adverse Events

Incidence and Risk Factors for Severe Adverse Events in a Prospective Cohort of HIV-Infected Adults Started on a Protease Inhibitor-Containing Therapy (Oral 56) Authored by X. Duval, V. Journot, T. May, C. Charlois, A. Waldner, C. Merle de Boev...

By Judith A. Aberg, M.D., F.I.D.S.A.

Metabolic and Virologic Responses to Different Regimens Vary by Gender and Race

Gender and Race Subgroup Analyses in a Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Trizivir (TZV), Combivir (COM)/Nelfinavir (NFV), or Stavudine (d4T)/Lamivudine (3TC)/NFV (Oral 57) Authored by K. Tashima, P. Kumar, A. Rodr...

By Judith A. Aberg, M.D., F.I.D.S.A.

Carotid Intima-Media Thickness in HIV-Infected and Uninfected Adults: ACTG 5078

Carotid Intima-Media Thickness in HIV-Infected and Uninfected Adults: ACTG 5078 (Oral 131) Authored by J. Currier, M. Kendall, K. Henry, F. Torriani, S. Storey, C. Shikuma, K. Mickelberg, B. Alston, M. Basar, R. Zackin, H. Hodis View the or...

By Judith A. Aberg, M.D., F.I.D.S.A.

Exposure to HAART Is Associated With an Increased Risk of Myocardial Infarction: The D:A:D Study

Exposure to HAART Is Associated With an Increased Risk of Myocardial Infarction: The D:A:D Study (Oral 130) Authored by N. Friis-Møller, R. Weber, A. D'Arminio Monforte, W. El-Sadr, P. Reiss, F. Dabis, L. Morfeldt, S. De Wit, C. Pradier, G. Cal...

By Judith A. Aberg, M.D., F.I.D.S.A.

High Replication Capacity Is Associated With High Baseline Viral Load in Untreated Subjects With Primary HIV Infection

High Replication Capacity Is Associated With High Baseline Viral Load in Untreated Subjects With Primary HIV Infection (Oral 152) Authored by S.J. Little, S.D.W. Frost, J.P. Routy, A.C. Collier, J.B. Margolick, E.S. Daar, R.A. Koup, B. Conway, ...

By Judith A. Aberg, M.D., F.I.D.S.A.

Evaluation of Coronary Artery Calcification by Electron Beam Computed Tomography in HIV-Infected Men Receiving Prolonged Protease Inhibitor Therapy

Evaluation of Coronary Artery Calcification by Electron Beam Computed Tomography (EBCT) in HIV-Infected Men Receiving Prolonged Protease Inhibitor (PI) Therapy (Oral 25) Authored by David M. Parenti, Madeline M. Rice, Afsoon Roberts, Angelike L...

By Judith A. Aberg, M.D., F.I.D.S.A.

Phenotyping and Therapeutic Drug Monitoring Complement Genotyping in Optimizing Therapy for HIV Patients

Phenotyping and Therapeutic Drug Monitoring Complement Genotyping in Optimizing Therapy for HIV Patients (Poster 458) Authored by Cynthia J. Carlyn, Aldona L. Baltch, Stratton VA Medical Ctr. & Albany Medical Coll., Albany, NY; Marty St. Cl...

By Judith A. Aberg, M.D., F.I.D.S.A.